Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Locally Advanced Nasopharyngeal Carcinoma
and you are
between 18 and 65
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

In this study, the investigators aim to compare the progression-free survival (PFS) and side effects of radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients with a satisfactory tumor response (complete response or partial response) after neoadjuvant chemotherapy (NACT).

Provided treatments

  • Drug: Docetaxel
  • Drug: Cisplatin
  • Radiation: IMRT/TOMO
  • Drug: Chemotherapy
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03015727. The sponsor of the trial is Zhejiang Cancer Hospital and it is looking for 440 volunteers for the current phase.
Official trial title:
Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma